safety and tolerability study of AZD7762 in combination with gemcitabine
Study identifier:D1040C00008
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Phase I, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability & Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination w/ Wkly Standard Dose Gemcitabine in Japanese Patients w/ Advanced Solid Malignancies
Medical condition
cancer
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD7762, gemcitabine
Sex
All
Actual Enrollment
24
Study type
Interventional
Age
20 Years - 74 Years
Date
Study Start Date: 01 Jul 2009
Estimated Primary Completion Date: 01 Feb 2011
Estimated Study Completion Date: 01 Feb 2011
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Other: AZD7762 + gemcitabine AZD7762 administered alone and in combination with gemcitabine | Drug: AZD7762 solution, intravenous, weekly Drug: gemcitabine intravenous, weekly Other Name: Gemzar |
Contacts
Investigators
Principal Investigator
Peter Langmuir
AstraZeneca
